OGEN - Oragenics shares drop 28% after pricing $5.25M stock offering

Oragenics (OGEN) plunges 28% premarket after pricing its public offering of ~14.2M common shares at $0.37/share, for expected gross proceeds of ~$5.25M.Underwriters' over-allotment is an additional 2,128,378 shares. Net proceeds will be used to fund pre-clinical development of SARS-CoV-2 vaccine, Terra CoV-2 and lantibiotics program, for general corporate purposes and working capital.A.G.P./Alliance Group Partners is acting as sole book-running manager.Closing date is November 24.Previously: Oragenics launches equity offering (Nov. 19)

For further details see:

Oragenics shares drop 28% after pricing $5.25M stock offering